Sanofi Pastuer dengue vaccine enters Phase III
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur’s dengue vaccine candidate became the first of its type to enter phase III with announcement by the company of a new clinical study in Australia, part of global phase III clinical study programme for the prevention of dengue disease in children and adults.